AZD3632

DRUG2 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Acute Lymphoblastic LeukaemiaAcute Myeloid LeukaemiaHigher-risk Myelodysplastic SyndromesRelapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

Phase 1

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

RecruitingNCT07155226

AstraZenecaAcute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes

Start: 2026-01-09End: 2029-02-15Target: 84Updated: 2026-07-20

A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression

RecruitingCTIS2025-521299-76-00

AstraZeneca ABRelapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

Start: 2025-12-18Target: 17Updated: 2025-12-10